

**Opexa Therapeutics (OPXA):** Opexa develops and commercializes cell therapies to treat autoimmune diseases such as MS, rheumatoid arthritis, and diabetes. The Company is focused on autologous (using patient's own cells) cellular therapy applications of its proprietary T-cell and stem cell therapies. The Company's lead product, Tovaxin, a T-cell therapy for multiple sclerosis is in Phase IIb trials.

The Company holds the exclusive worldwide license for adult multipotent (*partially differentiated*) stem cells derived from mononuclear cells of peripheral blood. The technology allows large quantities of monocyte (*white blood cells which can ingest dead or damaged cells and provide immunological defenses against many infectious organisms*) derived stem cells to be produced efficiently for use in autologous therapy, thus circumventing the threat of rejection. The Company is also in preclinical development for treatment of diabetes mellitus.